# WAKIX Q2 2026 Revenue Hits Record $261.3M, Beats Estimates; BP-205 Phase 1 Data Released

> news · REPORTED · 2026-08-04

Harmony Biosciences reported Q2 2026 net revenue of $261.3 million for WAKIX (pitolisant), representing 30% year-over-year growth and beating consensus estimates of $253.4 million. The company also shared initial Phase 1 single-ascending-dose data for its orexin-2 agonist BP-205 showing favorable pharmacokinetics and safety, and reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological diseases, with WAKIX (pitolisant) approved for narcolepsy and a pipeline including an orexin-2 agonist and Prader-Willi syndrome program.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/harmony-biosciences-announces-record-q2-2026-revenue-and-shares-initial-clinical-data-for-its-orexin-2-agonist-bp-205-reinforcing-potential-best-in-class-profile.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.